Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Autologous Bone Marrow Stem Cells in Ischemic Stroke.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT00535197
First received: September 25, 2007
Last updated: July 2, 2012
Last verified: July 2012

September 25, 2007
July 2, 2012
September 2007
July 2012   (final data collection date for primary outcome measure)
Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results [ Time Frame: Duration of study ] [ Designated as safety issue: Yes ]
safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results
Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results [ Time Frame: Duration of study ]
Complete list of historical versions of study NCT00535197 on ClinicalTrials.gov Archive Site
Improvement in clinical function as assessed by the Modified Rankin Score, and NIH stroke scale. [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Improvement in clinical function as assessed by the Modified Rankin Score, and NIH stroke scale. [ Time Frame: Duration of study ]
Not Provided
Not Provided
 
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
A Phase I/II Safety and Tolerability Study Following the Autologous Infusion of Immuno-selected CD34+ Subset Bone Marrow Stem Cells Into Patients With Acute Total Anterior Circulation Ischaemic Stroke

The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome (TACS/PACS).

The proposed trial will involve the recruitment of a total of 10 patients.

The cells will be collected from each subject recruited, via bone marrow sampling. CD34+ stem cells will then be isolated and harvested during a process of immuno-selection in accordance with the principles of Good Manufacturing Practice. The CD34+ cells will then be directly infused into the area of the stroke intra-arterially using the middle cerebral artery.

Initially, the investigator will monitor each patient for a period of 6 months post-stem cell infusion. Thereafter, they will revert to their previous treatment regime in the clinic.

Assessment of adverse events will be by physical examination and measurement of laboratory parameters. Assessment of efficacy will be by physical examination and the measurement of laboratory, CT and MRI parameters.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Stroke, Acute
  • Infarction, Middle Cerebral Artery
Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery
intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
Not Provided
Mackie AR, Losordo DW. CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J. 2011;38(5):474-85. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptoms and signs of clinically definite acute stroke
  • Time of stroke onset is known and treatment can be started within 7 days of onset
  • CT or MRI brain scanning has reliably excluded both intracranial haemorrhage and structural brain lesions which can mimic stroke (e.g. cerebral tumour)
  • The stroke is severe and conforming to the TACS phenotype (weakness, homonymous hemianopia and a focal cognitive deficit (e.g. aphasia) or reduction in consciousness) or PACS phenotype (two out of the three TACS criteria)
  • An age range of 30-80 years old
  • Stroke confined to MCA territory on CT or MRI brain imaging
  • NIHSS score >/= 8

Exclusion Criteria:

  • Known defect of clotting or platelet function (but patients on anti-platelet agents can enrol)
  • Haematological causes of stroke
  • Severe co-morbidity
  • Hepatic or renal dysfunction
  • The patient is female and of childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding
  • Hypo- or hyperglycaemia sufficient to account for the neurological symptoms; the patient should be excluded if their blood glucose is < 3.0 or > 20.0mmol/L
  • Patient is likely to be unavailable for follow-up e.g. no fixed home address
  • Patients with evidence of life threatening infection (e.g. HIV) or life threatening illness (e.g. advanced cancer)
  • Patient was already dependent in activities of daily living before the present acute stroke
  • Patients who have been included in any other clinical trial within the previous month
Both
30 Years to 80 Years
No
Contact: Jeremy Chataway, MA, BM BCH, PhD, MRCP (UK) 020 7886 6666 ext 6889 Jeremy.Chataway@imperial.nhs.uk
United Kingdom
 
NCT00535197
HHSC/003
Yes
Imperial College London
Imperial College London
Not Provided
Principal Investigator: Nagy Habib, Professor Imperial College London U.K.
Imperial College London
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP